The global market for polymerase chain reaction (PCR) technologies is projected to grow from $12.5 billion in 2021 to $18.3 billion by 2027, at an impressive compound annual growth rate (CAGR) of 8.0%. Several key factors are driving this robust market expansion.
Firstly, the rising incidence of infectious diseases, genetic disorders, and other targeted conditions is fueling demand for accurate and rapid diagnostic tools like PCR. Additionally, continued innovations in PCR technologies, along with increasing research funding and investments, are propelling the market forward. Moreover, the growing penetration of these technologies in emerging economies presents lucrative opportunities for market players.
However, the high costs associated with digital PCR (dPCR) instruments and certain technical limitations of quantitative PCR (qPCR) and dPCR are potential restraints on market growth during the forecast period.
Download a PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811
Market Dynamics
On the demand side, increasing investments, funds, and grants for research and development (R&D) in genomics and personalized medicine are boosting the adoption of PCR technologies. Government agencies and private organizations worldwide are recognizing the crucial role of qPCR and dPCR products in genomics research, leading to substantial funding initiatives.
Conversely, the high costs of dPCR instruments, which can range from $55,000 to $120,000 in the US, may limit their demand, especially among smaller research organizations and companies.
Emerging Opportunities and Challenges
Emerging markets, particularly in Asia, offer significant growth opportunities for PCR technologies. Rising healthcare expenditures, expanding infrastructure, and increasing awareness about genomic diagnostics in these regions are driving demand. However, the adoption and implementation of guidelines like the Minimum Information for Publication of Quantitative Real-time PCR Experiments (MIQE) remain a challenge, as they involve laborious preparation and considerations.
Market Segmentation
The reagents and consumables segment accounted for the largest share of the PCR technologies market in 2021, driven by the expanding applications of dPCR, increasing analytical procedures, and the rising availability of novel dPCR reagents worldwide.
The qPCR segment held the largest share by technique in 2021, owing to factors such as automation, growing adoption among researchers and healthcare professionals, and increased funding for qPCR-based research.
Geographically, North America dominated the market in 2021, while the Asia-Pacific region is expected to witness the highest CAGR during the forecast period, driven by healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostics, and growing awareness about gene-based disease diagnosis and treatment.
Prominent players in the PCR technologies market include Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Laboratories, QIAGEN, Takara Bio, Agilent Technologies, bioMérieux, Fluidigm Corporation, Danaher Corporation, Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Promega Corporation, Eppendorf AG, and Analytik Jena AG.
In conclusion, the PCR technologies market is poised for substantial growth, driven by increasing disease prevalence, technological advancements, and expanding applications in emerging economies. While challenges exist, the market’s prospects remain promising, fueled by continuous innovation and growing demand for accurate and efficient diagnostic tools.
